AstraZeneca Annual Report and Form 20-F Information 2011

Financial Statements4 ReservesSharepremiumaccount$mCapitalredemptionreserve$mOtherreserves$mProfitand lossaccount$mAt beginning of year 2,672 107 3,020 13,677 19,476 22,927Profit for the year – – – 2,961 2,961 2,043Dividends – – – (3,752) (3,752) (3,494)Amortisation of loss on cash flow hedge – – – 2 2 1Share-based payments – – (37) – (37) 98Share repurchases – 32 – (6,015) (5,983) (2,591)Issue of AstraZeneca PLC Ordinary Shares 406 – – – 406 492At end of year 3,078 139 2,983 6,873 13,073 19,476Distributable reserves at end of year – – 1,841 6,873 8,714 15,5182011Total$m2010Total$mAs permitted by section 408(4) of the Companies Act 2006, the Company has not presented its own profit and loss account.At 31 December 2011, $6,873m (31 December 2010: $13,677m) of the profit and loss account reserve was available for distribution. Includedin other reserves is a special reserve of $157m, arising on the redenomination of share capital in 1999.Included within other reserves at 31 December 2011 is $1,142m (31 December 2010: $1,179m) in respect of cumulative share-based paymentawards. These amounts are not available for distribution.5 Reconciliation of movement in shareholders’ fundsAt beginning of year 19,828 23,290Net profit for the financial year 2,961 2,043Dividends (3,752) (3,494)Amortisation of loss on cash flow hedge 2 1Share-based payments (37) 98Issue of AstraZeneca PLC Ordinary Shares 409 494Repurchase of AstraZeneca PLC Ordinary Shares (6,015) (2,604)Net decrease in shareholders’ funds (6,432) (3,462)Shareholders’ funds at end of year 13,396 19,8282011$m2010$mDetails of dividends paid and payable to shareholders are given in Note 21 to the Group Financial Statements on page 170.6 Share capitalAllotted, called-up and fully paidIssued Ordinary Shares ($0.25 each) 323 352Redeemable Preference Shares (£1 each – £50,000) – –323 3522011$m2010$mAt 31 December 2011, 1,292,355,052 Ordinary Shares were in issue.The Redeemable Preference Shares carry limited class voting rights and no dividend rights. This class of shares is capable of redemption at parat the option of the Company on the giving of seven days’ written notice to the registered holder of the shares.The movements in share capital during the year can be summarised as follows:No. of shares (m) $mAt 1 January 2011 1,409 352Issues of shares 11 3Repurchase of shares (128) (32)At 31 December 2011 1,292 323Share repurchasesDuring the year, the Company repurchased 128m Ordinary Shares at an average price of 2932 pence per share (2010: 54m Ordinary Shares atan average price of 3111 pence per share).Share schemesA total of 11m Ordinary Shares were issued during the year in respect of share schemes. Details of movements in the number of Ordinary Sharesunder option are shown in Note 24 to the Group Financial Statements; details of options granted to Directors are shown in the Directors’Remuneration Report.Shares held by subsidiariesNo shares in the Company are held by subsidiaries.196 Financial StatementsAstraZeneca Annual Report and Form 20-F Information 2011